Policy solutions to improve access to fertility treatment and optimise patient care: consensus from an expert forum
Infertility affects more than 17% of people of reproductive age globally, yet access to ART remains uneven and often out of reach.
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Michele Pistollato has extensive expertise in advising leading pharmaceutical companies and international trade associations on policy-related matters. He works to develop technical content to facilitate and enhance government and public affairs engagements, both internally with other functions and externally with key stakeholders.
Michele’s projects involve supporting the collaborative development of advocacy or research materials in partnerships between companies or between a company and patient representatives, physician societies, and academic experts. Michele specializes in policy topics ranging from the economics of pharmaceutical innovation, value assessment and pricing dynamics, to issues regarding specific therapy areas, such as oncology, cardiovascular diseases, and rare diseases.
Michele has published several health-policy related articles in peer-reviewed journals, including Atherosclerosis, BMC Medicine, Clinical Journal of the American Society of Nephrology, Frontiers in Pharmacology, International Journal of the Economics of Business, International Journal of Technology Assessment in Health Care, and Journal of Health Services Research & Policy. Many of the articles have been referenced by leading associations, such as the US Centers for Disease Control and Prevention (CDC) and the Organisation for Economic Co-operation and Development (OECD).
Michele holds a PhD in Economic Analysis from the Universitat Autònoma de Barcelona (Spain).
